Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05147233 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3 study of Inflammation Eye Pain and Postoperative Cataract, sponsored by Oculis.
- Completed
- Registry status
- Phase 3
- Development phase
- 241
- Enrollment target
- 20
- Study locations
NCT05147233: Completed Phase 3 study of Inflammation Eye Pain and Postoperative Cataract, sponsored by Oculis.
NCT05147233 is a Phase 3 study of Inflammation Eye Pain and Postoperative Cataract that has completed, run by Oculis. The registered enrollment target is 241 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05147233, a Phase 3 study of Inflammation Eye Pain and Postoperative Cataract, has completed, sponsored by Oculis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 241 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG OCS-01
Study Locations (20)
California
- Oculis Site 9 - Inglewood
- Oculis Site 23 - Newport Beach
- Oculis Site 26 - Petaluma
- Oculis Site 24 - San Pedro
- Oculis Site 22 - Westminster
Arizona
- Oculis Site 16 - Chandler
- Oculis Site 28 - Phoenix
Missouri
- Oculis Site 5 - St Louis
- Oculis Site 3 - Washington
Ohio
- Oculis Site 6 - Brecksville
- Oculis Site 14 - Cincinnati
Arkansas
- Oculis Site 8 - Fayetteville
Colorado
- Oculis Site 11 - Fort Collins
Florida
- Oculis Site 12 - Tamarac
Georgia
- Oculis Site 17 - Morrow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2022-06-24 |
| Est. Completion | 2023-07-03 |
| Phase | Phase 3 |
What the finished NCT05147233 record still lists
NCT05147233 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Inflammation Eye Pain appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT05147233 names 20 study sites across 13 states, led by California, Arizona, Missouri.
Frequently Asked Questions
What is clinical trial NCT05147233 about?
NCT05147233 is a clinical study titled "A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
What is the current status of trial NCT05147233?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 241 participants. The study started on 2022-06-24. Estimated completion is 2023-07-03.
What conditions does trial NCT05147233 study?
This clinical trial studies the following conditions: Inflammation Eye Pain, Postoperative Cataract.
What interventions are being tested in trial NCT05147233?
The interventions under investigation include: Vehicle (DRUG), OCS-01 (DRUG).
Who is sponsoring clinical trial NCT05147233?
This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05147233 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05147233's enrollment target sits among peer trials
241 1272nd of 2000 higher than 728 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI